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Acutely ill medical patients are at heightened risk for venous
thromboembolism, a term that combines deep vein throm-
bosis (DVT) and its more severe complication, pulmonary
embolism.1,2 Although the incidence of venous thromboem-
bolism inmedical patientsmight have been overestimated in
some instances, according to a recent study,3 treatment by
low, prophylactic doses of low molecular weight heparin
(LMWH) is recommended for these patientswhen additional
risk factors coexist.1,2 COVID-19 is an acute, complex disor-
der that is associated with SARS-CoV-2 infection, which, in
its most severe presentation, is characterized by the devel-
opment of interstitial pneumonia and acute respiratory
distress syndrome.4 According to many reports, COVID-19
exposes patients to a particularly high risk for venous
thromboembolism.5–8 Hence, hospitalized COVID-19
patients are generally treated with higher LMWH doses
than recommended for thromboprophylaxis. A recent docu-
ment by the Italian Drug Agency (AIFA) suggested the use of
80 to 100mg enoxaparin daily, instead of the usual 40mg,
while in some hospitals, even higher, up to full anticoagulant
doses of LMWH or unfractionated heparin9 are used. In our
hospital we use 40mg enoxaparin daily, as recommended for
high-risk, acutely ill medical patients.1,2
From the COVID-19 outbreak in Northern Italy until
April 14, 388patientshavebeenadmitted toour non-intensive
care unit (ICU) wards, none of whom developed symptomatic
DVTduring theirhospital stay.AsDVTmaybeasymptomatic in
a proportionof patients at risk,we performed leg compression
ultrasonography, which failed to detect DVT in any of the 64
tested patients, independently of the severity of their condi-
tion and length of in-hospital bed rest (►Table 1). The absence
of reports in the literature of DVT in COVID-19 patients under
LMWH thromboprophylaxis confirms our experience. This is
apparently in contrast with the relatively frequent reports of
pulmonary embolism in hospitalized COVID-19 patients,5–8
which is diagnosed based on the clinical observation of rapid
worsening of respiratory insufficiency and blood oxygenation
that is outof proportion to theextentof pulmonary infiltration
and on the evidence of pulmonary vessel occlusions, generally
interpreted as caused by pulmonary emboli, when computed
tomography angiography (CTA) is performed. These patients,
however, usually do not have symptoms or signs of DVT. As an
example, a study of 184 severe COVID-19 patients, all hospi-
talized in ICU and treated mostly with standard doses of
LMWH for thromboprophylaxis, reported a high incidence of
venous thromboembolism (n¼ 28).5 However, only one pa-
tient had DVT (diagnosed by compression ultrasonography),
while pulmonary embolism (diagnosed by CTA)was by far the
most frequent thrombotic event (n¼ 25) (highlighting the
importanceofperformingCTA in symptomatic patientswhen-
ever possible), followed by two cases of catheter-related upper
extremity venous thrombosis.5 The discrepancy between the
frequencies of pulmonary embolism and DVT is surprising,
because, although pulmonary embolism may occur in the
absence ofdetectableDVT, this happens in onlyapproximately
20% of studied patients.10 Therefore, we questionwhether the
observed pulmonary vessels occlusions that have been de-
scribed in reports onCOVID-19patients are exclusively caused
by pulmonary embolism. In our experience and in some
reports,11,12 filling defects of pulmonary vessels that are
detectedbyCTA scans are inmany instancesmore reminiscent
of pulmonary thrombi rather than emboli, because they are
not fully occlusive. This observation is compatible with post-
mortem descriptions of “…presence of manifestations of
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thrombotic, or thrombo-hemorrhagic microangiopathy…; …
enlarged pulmonary blood vessels containing micro-
thrombi….” Diffuse thrombotic material is observed also in
other organs, compatibly with the development of clinical
signs of multiorgan failure.13 Therefore, local thrombi both in
the lungsandotherorgans, rather thanemboli fromperipheral
veins, appear to be thehallmarkof severe COVID-19,which are
responsible for the severe ischemic clinical manifestations of
the disease.
Distinction between pulmonary thrombi and pulmonary
emboli is not trivial, because their pathogenesis and, hence,
treatment are arguably different. If the rarity of DVT in our
COVID-19 patients and also in other more severe patients
described in the literature strongly suggests that prophylac-
tic LMWH is effective in preventing VTE, it is quite evident
that the same treatment is not effective to prevent pulmo-
nary thrombosis in COVID-19 patients. Higher LMWH doses
may not be necessarily more effective, considering that
anticoagulant doses of heparin are not indicated for treat-
ment of other types of thrombotic microangiopathies, which
possibly share some pathogenicmechanismswith the COVID
microangiopathy,14 with the exception of catastrophic anti-
phospholipid syndrome.15 Pulmonary thrombi in COVID-19
probably develop as a consequence of vascular damage
associated with viral infection and severe inflammation,
with the pathogenic contribution of platelets interacting
with the vascular wall and leukocytes (contributing to boost
inflammation), factor XIIa with other components of the
contact phase of coagulation, von Willebrand factor, com-
plement, and other players in thromboinflammation,16–24
some of which have been shown to be implicated in the
pathogenesis of acute respiratory distress syndrome already
many years ago.25 High-dose heparin in this setting may not
only be ineffective, but it may also be dangerous, possibly
contributing to the described hemorrhagic component of
microangiopathy. While only randomized clinical trials can
answer this question, it is well established that high-dose
LMWH administration is associated with increased inci-
dence of major and fatal bleeding (which actually occurred
in some COVID-19 Italian patients, most likely in association
with the high degree of anticoagulation).
Pending the results of randomized clinical trials, which
will hopefully test not only high-dose heparin, but also drugs
targeting platelets, vonWillebrand factor, complement, con-
tact phase of coagulation, and/or other players in thromboin-
flammation,webelieve that we should continue to use 40mg
enoxaparin for thromboprophylaxis of COVID-19 patients, at
least in non-ICU wards.
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